Apellis Pharmaceuticals, Inc. (APLS) Misses Q1 EPS by 7c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q1 EPS of ($0.54), $0.07 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $172.3 million versus the consensus estimate of $161.36 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Stifel Reiterates Buy Rating on FedEx (FDX) Ahead of Q4 Earnings
• Worried the AI trade has gone too far? Evercore likes these 4 stocks